Clinical Research Directory

Inclusion Criteria: * Adenocarcinoma of the prostate with intermediate risk disease T2b-T2c or Gleason score 7 or prostate specific antigen (PSA) 10-20 ng/ml, without metastatic disease * To rule out metastatic disease, patients must have the following tests: * Bone scan within 60 days prior to registration * Computed tomography (CT) of abdomen/pelvis within 60 days prior to registration * Karnofsky performance status \> 70 * Age \> 18 * PSA blood test within 60 days prior to registration * Prostate biopsy within 180 days prior to registration * Within 60 days prior to registration, hematologic minimal values: * Absolute neutrophil count \> 1,500/mm\^3 * Hemoglobin \> 8.0 g/dl * Platelet count \> 100,000/mm\^3 * Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter * No history of previous pelvic irradiation Exclusion Criteria: * History of urological surgery or procedures predisposing to GU complications after radiation, i.e., anastomoses, stricture repair, etc. (will be determined by radiation oncologist) * History of prior pelvic irradiation * Documented distant metastatic disease * Prior radical prostatectomy or cryosurgery for prostate cancer